Table 1

Efficacy of the second anti-TNF assessed by DAS28 (mean±SD) and HAQ (mean±SD), reductions at 6 months from baseline, accordning to the type of previous antiTNF and reason for discontinuation. (Number of patients)

		DeltaDAS28 6m		DeltaHAQ 6m
First anti-TNF	Second anti-TNF	Mean±SD	p Value^*	Mean±SD	p Value^*
ETA	ADA	0.93±1.21 (154)	0.34	0.12±0.43 (164)	0.70
	INF	1.24±1.40 (36)		0.18±0.44 (36)
ADA	ETA	1.39±1.46 (121)	0.88	0.25±0.44 (127)	0.25
ADA	INF	0.91±1.16 (10)	0.88	–0.02±0.67 (10)	0.25
INF	ETA	1.75±1.47 (145)	0.30	0.26±0.57 (145)	0.82
INF	ADA	1.16±1.56 (63)	0.30	0.19±0.43 (68)	0.82
Reason discontinuation first anti-TNF
Intolerance	ETA	1.68±1.47 (62)	0.85	0.30±0.46 (61)	0.17
	INF	1.32±0.90 (6)		0.20±0.11 (5)
	ADA	1.24±1.79 (46)		0.06±0.42 (53)
Primary inefficacy	ETA	1.56±1.45 (82)	0.13	0.25±0.58 (87)	0.86
	INF	1.23±1.33 (17)		0.13±0.66 (19)
	ADA	1.02±1.03 (63)		0.16±0.40 (65)
Secondary inefficacy	ETA	1.65±1.41 (83)	0.02^†	0.25±0.48 (86)	0.92
	INF	1.04±1.11 (12)		0.14±0.50 (10)
	ADA	0.99±1.16 (59)		0.20±0.45 (62)

↵* adjusted for BL age, sex, DAS28, conc DMARDs and glucocorticoids.
↵† ETA vs ADA p=0.005.